In Australia, about 43% of people aged between 16 and 85 had experienced a mental disorder at some point as of 2023. Between 2021 and 2022, over 44 million mental health-related meds, largely anti-depressants, were dispensed. While traditional treatments are only about 20 to 30% effective in treating anxiety and depression, recreational cannabis company Melodiol
Read MoreAfter changing its name and identity, cannabis and psychedelics provider Melodiol (ASX: ME1) has decided to sell off two of its most prominent business units, Sierra Sage Herbs and Halucenex Life Sciences to US-based Panacea Life Sciences for $7.56 million in cash and shares. Panacea Life Sciences focuses on the production, research, and distribution of
Read MoreAccording to the Australian Department of Health, half of us will experience some form of mental illness in our lifetime. Treatment is somewhat limited to prescription medications and psychotherapy. However, the current mental health crisis has seen researchers and practitioners alike wondering- is there a better way to approach these frighteningly common conditions? Enter psychedelics,
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.